EGFR and non-small cell lung carcinoma: In NSCLC with overexpressed EGFR, the inhibition of the receptor signaling has been introduced as a targeted treatment, with tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, rendered optimal in carriers of EGFR-activating mutations [21, 28, 29].